Patamostat (E-3123) is a potent protease inhibitor that effectively inhibits trypsin, plasmin, and thrombin, exhibiting IC50 values of 39 nM, 950 nM, and 1.9 µM, respectively. Research suggests that Patamostat might suppress the pathogenesis and development of acute pancreatitis [1] [2].

Patamostat, administered through intravenous infusion, demonstrates dose-dependent efficacy in reducing mortality in rats (0.03-0.3 mg/kg) and rabbits (0.3-3.0 mg/kg) following pancreatitis induction. In dogs afflicted with pancreatitis, patamostat in doses ranging from 1.0 to 3.0 mg/kg mitigates the elevation of serum trypsin and lipase levels. A specific study with male Wistar rats, using a continuous infusion of 2 mg/kg per hour of patamostat, showcases significant improvements across multiple parameters. These include a reduction in mortality rate, serum and ascitic fluid amylase levels, plasma endotoxin and serum Fibrin Degradation Products (FDP) levels, and normalized distribution of lysosomal enzyme. This study involved male Wistar rats, averaging a weight of about 350 g, with the dosage administered continuously per hour for 1 h, resulting in notably enhanced survival rates.